Drug Profile
Research programme: spinal muscular atrophy gene therapy - Tapestry Pharmaceuticals
Alternative Names: Spinal muscular atrophy gene therapy research programme - Tapestry PharmaceuticalsLatest Information Update: 10 Aug 2005
Price :
$50
*
At a glance
- Originator Tapestry Pharmaceuticals
- Class Gene therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Spinal muscular atrophy
Most Recent Events
- 10 Aug 2005 Discontinued - Preclinical for Spinal muscular atrophy in USA (unspecified route)
- 22 Jun 2005 Preclinical trials in Spinal muscular atrophy in USA (unspecified route)